Linezolid-Induced Pure Red Cell Aplasia: A Case Report

References

• Ager S, Gould K. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect Drug Resist. 2012;5:87–102. doi:10.2147/IDR.S25890
   PubMedGoogle Scholar
• Sotgiu G, Centis R, D’Ambrosio L, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40(6):1430–1442. doi:10.1183/09031936.00022912
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Ward SC, Crist CJ, et al. In vitro activities of linezolid against multiple nocardia species. Antimicrob Agents Chemother. 2001;45(4):1295–1297. doi:10.1128/AAC.45.4.1295-1297.2001
   Web of Science ®Google Scholar
• Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA. 2001;285(10):1291. doi:10.1001/jama.285.10.1291
   PubMed Web of Science ®Google Scholar
• Kraleti S, Soultanova I. Pancytopenia and lactic acidosis associated with linezolid use in a patient with empyema. J Ark Med Soc. 2013;110(4):62–63.
   PubMedGoogle Scholar
• Woytowish MR, Maynor LM. Clinical relevance of linezolid-associated serotonin toxicity. Ann Pharmacother. 2013;47(3):388–397. doi:10.1345/aph.1R386
   PubMed Web of Science ®Google Scholar
• Vishnu VY, Modi M, Goyal MK, et al. Linezolid induced reversible peripheral neuropathy. Am J Ther. 2016;23(6):e1839–e1841. doi:10.1097/MJT.0000000000000359
   Web of Science ®Google Scholar
• Ishii N, Kinouchi R, Inoue M, et al. Linezolid-induced optic neuropathy with a rare pathological change in the inner retina. Int Ophthalmol. 2016;36(6):761–766. doi:10.1007/s10792-016-0196-5
   PubMed Web of Science ®Google Scholar
• Hu W, Shi B, Liu L, et al. Linezolid induced twice pure red cell aplasia in a patient with central nervous system infection after allogeneic stem cell transplantation. Iran J Pharm Res. 2016;15(2):647–651.
   Web of Science ®Google Scholar
• Monson T, Schichman SA, Zent CS. Linezolid-induced pure red blood cell aplasia. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. Clin Infect Dis. 2002;35(3):E29–31. doi:10.1086/340982
   PubMed Web of Science ®Google Scholar
• Taketani T, Kanai R, Fukuda S, et al. Pure red cell precursor toxicity by linezolid in a pediatric case. J Pediatr Hematol Oncol. 2009;31(9):684–686. doi:10.1097/MPH.0b013e3181b1ed42
   Web of Science ®Google Scholar
• Waki F, Ohnishi H, Shintani T, et al. Linezolid-induced pure red cell aplasia in a patient with Staphylococcus epidermidis infection after allogeneic stem cell transplantation. Transpl Infect Dis. 2012;14(4):E1–6. doi:10.1111/j.1399-3062.2012.00728.x
   PubMed Web of Science ®Google Scholar
• Luo Z, Xu N, Wang Y, et al. Linezolid-induced pure red cell aplasia: a case report and literature review. J Int Med Res. 2018;46(11):4837–4844. doi:10.1177/0300060518800126
   PubMed Web of Science ®Google Scholar
• Soriano A, Miro O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med. 2005;353(21):2305–2306. doi:10.1056/NEJM200511243532123
   PubMed Web of Science ®Google Scholar
• Garrabou G, Soriano À, Pinós T, et al. Influence of mitochondrial genetics on the mitochondrial toxicity of linezolid in blood cells and skin nerve fibers. Antimicrob Agents Chemother. 2017;61(9):e00542–17. doi:10.1128/AAC.00542-17
   PubMed Web of Science ®Google Scholar
• Nagiec EE, Wu L, Swaney SM, et al. Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis. Antimicrob Agents Chemother. 2005;49(9):3896–3902. doi:10.1128/AAC.49.9.3896-3902.2005
   PubMed Web of Science ®Google Scholar
• McKee EE, Ferguson M, Bentley AT, et al. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother. 2006;50(6):2042–2049. doi:10.1128/AAC.01411-05
   PubMed Web of Science ®Google Scholar
• Senneville E, Legout L, Valette M, et al. Risk factors for anaemia in patients on prolonged linezolid therapy for chronic osteomyelitis: a case-control study. J Antimicrob Chemother. 2004;54(4):798–802. doi:10.1093/jac/dkh409
   PubMed Web of Science ®Google Scholar
• Wu VC, Wang YT, Wang CY, et al. High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease. Clin Infect Dis. 2006;42(1):66–72. doi:10.1086/498509
   PubMed Web of Science ®Google Scholar
• Tsuji Y, Hiraki Y, Matsumoto K, et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother. 2011;17(1):70–75. doi:10.1007/s10156-010-0080-6
   PubMed Web of Science ®Google Scholar
• Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy. 2007;27(3):476–479. doi:10.1592/phco.27.3.476
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Orlando G, Cozzi V, et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents. 2013;41(6):586–589. doi:10.1016/j.ijantimicag.2013.02.020
   PubMed Web of Science ®Google Scholar
• Legout L, Valette M, Dezeque H, et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia? J Antimicrob Chemother. 2010;65(10):2224–2230. doi:10.1093/jac/dkq281
   Web of Science ®Google Scholar
• Youssef S, Hachem R, Chemaly RF, et al. The role of vitamin B6 in the prevention of haematological toxic effects of linezolid in patients with cancer. J Antimicrob Chemother. 2008;61(2):421–424. doi:10.1093/jac/dkm506
   Web of Science ®Google Scholar